Larvol Delta - Discovery-of-CID078-a-firstinclass-oral-macrocycle-cyclin-ABRxL-inhibitor-for-the-treatment-of-cancers-with-RB1-loss-or-hyperactivated-E2F

CID-078 - Circle Pharma

https://www.abstractsonline.com/pp8/#!/21436/presentation/2838

M. Evangelista

Mar 28, 2026

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next